Singapore start-up selected as a finalist for Falling Walls Breakthrough of the Year 2020

Singapore Startup Proteona selected as a Falling Walls Breakthrough of the Year Finalist, Science Start-Up

Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology

Proteona is proud to be selected as a Science Start-Up Breakthrough of the Year finalist in the Falling Walls Remote 2020. It is the first time that this prestigious event is hosted online (for free), so do join us from 1-10 November to catch our video presentation and to attend the exciting line up of events.

In the video, we will explain why Proteona embarked on the mission of breaking the wall of cancer, and how we are going to do that. We will talk about

  • The current challenges in targeted cancer therapy and precision medicine
  • Why tumor heterogeneity or diversity makes cancer so difficult to treat
  • How we tackle the problem by combining single cell multi-omics and artificial intelligence-assisted analysis
  • What we are doing now to help multiple myeloma patients
  • Our plan to break the wall of cancer, one cell at a time

Follow us on LinkedIn to stay updated when the video will be released!

Our LinkedIn Page

The Falling Walls Conference is a world science summit that highlights the latest scientific and social breakthroughs. It first took place on November 9th, 2009, 20 years since the fall of the Berlin Wall. Since then, it features the top innovations in all fields of science around the world, showcasing how innovation can make a positive impact. We are excited to see you there!

Register for Falling Walls Remote 2020

Check out the past Falling Walls Venture finalists

Meet the distinguished panel of juries for “Falling Walls Start-Up of the year” 2020

For media queries, please contact:

Dr Andreas Schmidt

About Proteona

Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.